Showing results (131-140 of 150) with videos related to
Sort By:
Pageof 15
Cancers|October 3, 2019
Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN StudyMartina Morini, Davide Cangelosi, Daniela Segalerba, et al.The Lancet. Oncology|November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.Cancer|February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastomaSteven G DuBois, Chitose Ogawa, Lucas Moreno, et al.Cancers|July 2, 2021
Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint StudyMassimo E Abate, Silvia Cammelli, Letizia Ronchi, et al.Cancers|February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.Journal of Neuro-Oncology|July 9, 2022
How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatmentMaura Massimino, Sabina Vennarini, Francesco Barretta, et al.Cancer|February 24, 2022
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2)Emanuela Palmerini, Cristina Meazza, Angela Tamburini, et al.Pediatric Blood & Cancer|January 20, 2025
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority TrialRoberto Luksch, Emanuela Palmerini, Giuseppe Maria Milano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Ewing Sarcoma: Current Management and Future Approaches Through CollaborationNathalie Gaspar, Douglas S Hawkins, Uta Dirksen, et al.Pageof 15